Conversion From Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients With Gastrointestinal Tract Disorders

Improvement in Severe Mycophenolic Acid-associated Gastrointestinal Symptoms after Changing Enteric-coated Mycophenolate Sodium to Mizoribine in Renal Transplant Recipients: Two Case Reports

“…Previous studies have shown that the mycophenolic acid dosage is better maintained with entericcoated mycophenolate sodium than mycophenolate mofetil, with fewer gastrointestinal symptoms in recipients receiving enteric-coated mycophenolate sodium (4,5). The benefits of changing renal transplant recipients who develop gastrointestinal symptoms while on mycophenolate mofetil therapy to enteric-coated mycophenolate sodium were recently established in many studies (6,7). However, our experience reveals that patients who have been treated with enteric-coated mycophenolate sodium may still experience gastrointestinal symptoms.…”

Enteric-coated Mycophenolate Sodium as a Corticosteroid-sparing Agent for the Treatment of Autoimmune Scleritis

“…In a large prospective study of the use of MMF in renal organ transplant patients, AEs were as high as 50%. 10 In contrast, long-term administration of EC-MPS has been reported to be effective and safe in organ transplant patients. 10,14,[17][18][19][20] Some studies have compared the safety of EC-MPS with that of MMF.…”

“…10 In contrast, long-term administration of EC-MPS has been reported to be effective and safe in organ transplant patients. 10,14,[17][18][19][20] Some studies have compared the safety of EC-MPS with that of MMF. 19,20 A multicenter, openlabel, prospective study reported that in patients with moderate to severe gastrointestinal symptoms, a change in treatment from MMF to EC-MPS significantly reduces gastrointestinal symptoms and improves the quality of life.…”

“…5,8,9 This gastrointestinal burden was proven to be the result of direct irritation from MMF. 10 Oral corticosteroids and NSAIDs, which also have adverse gastroenteric effects, have been commonly used in the treatment of rheumatic diseases. Combination therapy with MMF and oral corticosteroids/NSAIDs increases the risk of gastroenteropathy.…”

“…11,12 It has been reported that EC-MPS (720 mg twice daily) is therapeutically equivalent to MMF (1000 mg twice daily) in organ transplant patients [12][13][14] and is associated with fewer AEs. 10,12,13,15 Here, we report our experience of using EC-MPS as a corticosteroid-sparing agent for the treatment of autoimmune scleritis.…”